Jury awards $285K in Fosamax case 
By:
Kimberly Atkins
Published: February 20, 2013
Tags: bellwether trial, bone decay, federal court, Fosamax, verdicts
In the latest bellwether case to go to trial over the osteoporosis drug Fosamax, a New York federal jury has awarded $285,000 to a woman who suffered injuries to her jaw after using the drug.
Fosamax suit can’t proceed based on ‘sham’ issue
Published: February 4, 2013
Tags: expert testimony, failure to warn, Fosamax, Merck, osteonecrosis, product liability
Irreconcilable contradictions in expert testimony prevented a product liability plaintiff from establishing that Merck failed to provide adequate warnings with the osteoporosis drug Fosamax, the 2nd Circuit has ruled in affirming judgment.
Fosamax litigation ready for next step in bellwether cases
By:
Correy Stephenson
Published: December 4, 2012
Tags: drug litigation, femur fracture, Fosamax, Merck, multidistrict litigation, osteonecrosis
Six years after the first Fosamax lawsuit was filed, litigation over the osteoporosis drug is about to start a new chapter.
The suits against Merck, the drug’s manufacturer, fall into two categories: plaintiffs alleging they suffer from osteonecrosis, or jaw damage, and those claiming they suffered a non-traumatic femur fracture as a result of taking the drug.
Fosamax claims aren’t subject to tolling
Published: March 6, 2012
Tags: class actions, equitable tolling, Fosamax, product liability, statute of limitations
The pendency of a Fosamax class action in another jurisdiction did not toll the statute of limitations for individual Fosamax claims, the Virginia Supreme Court has ruled in answering certified questions from the 2nd Circuit.
Special master appointed to help settle Fosamax cases
Published: December 7, 2011
Tags: Fosamax, Merck, osteonecrosis, osteoporosis
After mixed results in bellwether cases, and a recent string of defense verdicts, a special settlement master has been appointed to the Fosamax multidistrict litigation.
Fosamax bone fracture lawsuits consolidated
Published: June 10, 2011
Tags: FDA, Food and Drug Administration, Fosamax, multidistrict litigation, osteoporosis
Lawsuits alleging that the osteoporosis drug Fosamax causes bone fractures have been consolidated in multidistrict litigation in federal court in New Jersey.
First state trial in Fosamax case ends with defense win
By:
Sylvia Hsieh
Published: February 25, 2011
Tags: drug litigation, Fosamax, multidistrict litigation, osteonecrosis, osteoporosis
In the first bellwether state trial over the osteoporosis drug Fosamax, Merck won a defense verdict last week.
Plaintiff’s attorney in Fosamax case appeals sanction
By:
Tony Ogden
Published: October 27, 2010
Tags: Fosamax, Sanctions
The attorney for the plaintiff in the second trial of the ongoing Fosamax litigation has filed an appeal after the judge in the case sanctioned him for his courtroom behavior.
Fosamax verdict reduced, counsel sanctioned
By:
Correy Stephenson
Published: October 7, 2010
Tags: Fosamax, remittitur, Sanctions
An $8 million verdict for a plaintiff who suffered from osteonecrosis of the jaw after taking Fosamax is excessive, and the plaintiff must choose between a new trial on damages or a remittitur to $1.5 million, a U.S. District Court has ruled.
Next Fosamax trial nears
By:
Nora Tooher
Published: September 21, 2010
Tags: Fosamax, Merck, osteonecrosis, product liability
Jury selection in the third Fosamax bellwether trial is slated for Oct. 28 in U.S. District Court for the Southern District of New York.
